ASTRAZEN - Fundamental Analysis: Financial Health & Valuation

Last Updated Time : 20 Dec 25, 11:14 pm

Fundamental Rating: 3.9

📊 Core Financials:

- Profitability: PAT improved from 83.8 Cr. to 105 Cr. (+16.8% QoQ), showing growth momentum.

- Margins: ROCE at 139% and ROE at 200% are exceptionally high, though may reflect accounting adjustments or one-off gains.

- Debt: Debt-to-equity at 0.28 → low leverage, strong balance sheet.

- EPS: 5.79 ₹, modest earnings relative to valuation.

💹 Valuation Indicators:

- P/E: 91.8 vs Industry PE of 51.8 → significantly overvalued.

- P/B: 598 ₹ / 85.6 ₹ ≈ 6.99, steep premium to book value.

- PEG Ratio: 0.30 → attractive, suggesting undervaluation relative to growth.

- Intrinsic Value: Estimated fair value ~520–540 ₹, suggesting current price is moderately overvalued.

🏢 Business Model & Competitive Advantage:

Aster DM Healthcare operates hospitals, clinics, and pharmacies across India and the Middle East. Competitive advantage lies in diversified healthcare services, strong brand presence, and geographic spread. While growth is evident, valuations remain stretched and earnings modest compared to price levels.

📈 Entry Zone & Long-Term Guidance:

- Entry Zone: Attractive accumulation range between 520–540 ₹.

- Long-Term Holding: Suitable for long-term investors seeking exposure to healthcare growth, though premium valuations and modest EPS warrant cautious entry.

Positive

• Strong PAT growth (+16.8% QoQ) indicates improving performance.
• Exceptional ROCE (139%) and ROE (200%) highlight efficiency, though may be inflated by one-offs.
• Debt-to-equity at 0.28 → low leverage, strong financial stability.
• DII holdings increased (+1.04%), showing domestic institutional support.

Limitation

• High P/E ratio (91.8) compared to industry average (51.8).
• P/B ratio of 6.99 reflects steep premium valuation.
• EPS of 5.79 ₹ is modest relative to price.
• Technical weakness: RSI at 26.7 and MACD (-18.4) reflect bearish sentiment.

Company Negative News

• FII holdings decreased (-0.92%), showing reduced foreign investor confidence.
• Technical indicators (MACD negative, RSI oversold) show short-term weakness.
• Premium valuation compared to peers.

Company Positive News

• Quarterly PAT growth highlights improving performance.
• DII holdings increased, showing domestic institutional confidence.
• Strong brand presence in healthcare sector with diversified services.

Industry

• Healthcare sector supported by rising demand for hospitals, diagnostics, and preventive care.
• Industry PE at 51.8 indicates moderate valuation compared to Aster’s premium.
• Sector growth expected with increasing healthcare awareness and infrastructure expansion.

Conclusion

⚖️ Aster DM Healthcare demonstrates strong fundamentals with improving profitability, low debt, and sector tailwinds. However, high valuations and modest EPS limit near-term attractiveness. Investors should consider entry near 520–540 ₹ for value-conscious positioning, with long-term holding viable for those seeking exposure to healthcare growth.